Shu-Gan-Liang-Xue decoction simultaneously down-regulates expressions of aromatase and steroid sulfatase in estrogen receptor positive breast cancer cells

Han

Molecular Medicine Reports

et al. 2014

Aromatase inhibitors (AIs) are widely used in the treatment of hormone-dependent breast cancer and as a result, aromatase inhibitor-associated bone loss (AIBL) has become a major concern amongst patients receiving AI treatment. Modified Shu-Gan-Liang-Xue decoction (mSGLXD), a clinical prescription, has been used for ameliorating AIBL in patients with breast cancer for decades and has achieved good clinical efficacy. However, the mechanism underlying how mSGLXD influences bone homeostasis and alleviates AIBL has remained elusive. In the present study, mSGLXD was supplemented with Rhizoma Drynariae containing phytoestrogens, and the safety of mSGLXD was evaluated. mSGLXD did not possess estrogenic activity and significantly inhibited the proliferation of estrogen receptor-positive breast cancer cell line MCF-7, which suggested that mSGLXD was safe for postmenopausal patients with breast cancer. Subsequently, the effects of mSGLXD alone or in combination with anastrozole on osteoblastic MC3T3-E1 cell proliferation and differentiation were investigated. Cell counting kit-8, reverse transcription-polymerase chain reaction and biochemical methods, such as ELISA and alizarin red S staining, were used in the present study. It was revealed that mSGLXD not only stimulated MC3T3-E1 cell proliferation, but also upregulated alkaline phosphatase and osteocalcin gene and protein expression levels. High concentrations of anastrozole (10 or 100 μmol/l) markedly inhibited MC3T3-E1 cell proliferation, but this inhibitory effect was attenuated by mSGLXD. Furthermore, mSGLXD increased MC3T3-E1 cell mineralization following β-glycerophosphate and ascorbic acid induction. Therefore, the results of the present study suggested that mSGLXD may be a promising adjuvant therapy, with high safety and efficacy, for the prevention and treatment of AIBL in patients with breast cancer who receive AI treatment.

Section: Discussionmentioning

confidence: 90%

Effects of modified Shu-Gan-Liang-Xue decoction combined with anastrozole on osteoblastic proliferation and differentiation of MC3T3-E1 cells

Han

Molecular Medicine Reports

et al. 2014

“…Sarcococca saligna, the sweet box or Christmas box, native from Northern Pakistan, contains phytochemical constituents such as alkaloid-C, dictyophlebine, sarcovagine-D and saracodine, which inhibit aromatase [86]. Shu-Gan-Liang-Xue decoction (SGLXD) is a traditional Chinese herbal formula with a potential dual aromatase-sulfatase inhibitor by simultaneously down-regulating the expressions of aromatase and sulfatase in BCa cell cultures [87]. SGLXD also has anti-tumor effects on the BCa cells ZR-75-1 by inhibiting aromatase and steroid sulfatase [88].…”

Section: Natural Compounds Inhibiting the Steroid Synthesismentioning

confidence: 99%

“…Melatonin [44] Naringin, apigenin, berberine, palmatine, bavachin, jatrorrhizine, bavachinin [80] Alangenes [82] Extracts of Brassaiopsis glomerulata [84] Bakuchiol [85] Extracts of Sarcococca saligna [86] Shu-Gan-Liang-Xue decoction [87,88] Aqueous extracts of white button mushrooms [90] Butein [89] Obacunone [91] 5α-reductase Finasteride [53] Dutasteride [54] Serenoa repens extracts [92] Ethanolic extracts of Epilobium angustifolium [93] (−)-epigallocatechin gallate, biochanin A, daidzein, genistein, kaempferol [94] caffeic acid, grandifloroside [95] polyphenols from Cynomorium songaricum [96] Androgen receptor (SARM) Bicalutamide [65] Enzalutamide [69] Darolutamide [71] Methanolic extract of Brosimum rubescens bark [98] 3,3 -diindolylmethane [99] Androgen receptor (SARD) Darolutamide derivatives [79] Tanshinone IIA [100] Ethanolic extracts from propolis [101] Estrogen receptor (SERM)…”

Section: Pharmacological Targets Synthetic Compounds Natural Compoundsmentioning

confidence: 99%

Pharmacological Modulation of Steroid Activity in Hormone-Dependent Breast and Prostate Cancers: Effect of Some Plant Extract Derivatives

Bayala

Zoure

Baron

et al. 2020

IJMS

The great majority of breast and prostate tumors are hormone-dependent cancers; hence, estrogens and androgens can, respectively, drive their developments, making it possible to use pharmacological therapies in their hormone-dependent phases by targeting the levels of steroid or modulating their physiological activity through their respective nuclear receptors when the tumors relapse. Unfortunately, at some stage, both breast and prostate cancers become resistant to pharmacological treatments that aim to block their receptors, estrogen (ER) or androgen (AR) receptors, respectively. So far, antiestrogens and antiandrogens used in clinics have been designed based on their structural analogies with natural hormones, 17-β estradiol and dihydrotestosterone. Plants are a potential source of drug discovery and the development of new pharmacological compounds. The aim of this review article is to highlight the recent advances in the pharmacological modulation of androgen or estrogen levels, and their activity through their cognate nuclear receptors in prostate or breast cancer and the effects of some plants extracts.

“…Appropriate safety of SGLXD has been shown in herb-drug safety/interaction studies [39,59,73,[76][77][78][79][80][81][82][83][84][85][86][87][88][89]. This preliminary research has been limited to China, with Chinese breast cancer survivors and in a Chinese hospital setting.…”

Section: Am J Biomed Sci and Resmentioning

confidence: 99%

Chinese Herbal Medicine to Alleviate Vasomotor Symptoms in Breast Cancer Survivors: A Study Protocol for a Randomised, Double Blind, Placebo Controlled, Multi Centre, Cross Over Trial

Porter

Zhu

et al. 2020

AJBSR